• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Ethical Issues in International Biomedical Research

Ethical Issues in International Biomedical Research

A Casebook

9780195179224
442,26 zł
398,03 zł Zniżka 44,23 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 398,03 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
Ethical Issues in International Biomedical Research is the definitive book on the ethics of research involving human subjects in developing countries. Using 21 actual case studies, it covers the most controversial topics, including the ethics of placebo research in Africa, what benefits should be provided to the community after completion of a research trial, how to address conflicts between IRBs in developed and developing countries, and undue inducement of poor people indeveloping countries. Each case is accompanied by two expert commentaries, written by many of the worlds leading experts in bioethics as well as new voices with research experience in developing countries. No other volume has this scope.
Szczegóły produktu
OUP USA
85041
9780195179224
9780195179224

Opis

Rok wydania
2007
Numer wydania
1
Oprawa
twarda
Liczba stron
400
Wymiary (mm)
163 x 241
Waga (g)
686
  • FOREWORD; INTRODUCTION; SECTION I: COLLABORATIVE PARTNERSHIP; Case 1. Community involvement in biodiversity prospecting in Mexico; Case 2. Selling genes: consulting a genetic population database in Tonga; Case 3: Substantiality of a fluoride varnish feasability study in Nicaragua; SECTION II: SCIENTIFIC VALIDITY; Case 4: Malarone testing in pregnant women in Thailand; Case 5: Neglected diseases: Incentives to Conduct Research in Developing Countries: the case of Pharamomycin for visceral leishmaniasis in India; SECTION III: SCIENTIFIC VALIDITY; Case 7. The limitations of knowledge: equipsoise and a randomized treatment strategy for malaria in Ethiopia; Case 8. Controversy surrounding the scientific value of the Vaxgen/Aventis (RV-144) Phase III; SECTION IV: FAIR SUBJECT AND COMMUNITY SELECTION; Case 9. Pharmaceutical research in developing countries: testing a new sufracant in Bolivia; Case 10: Trading Genes for Toothbrushes: Research with the Aka Pygmy people in the Central African Republic; Case 11: Test Phase I malaria vaccine: where should the research be conducted?; SECTION V: FAVOURABLE RISK/BENEFIT ASSESSMENT; Case 12: Ethical complcations during an investigation of malaria infection in native Amazonian populations in western Brazil; Case 13: Access to treatment for trial participants who become infected with HIV during the course of Phase I trials of a preventive HIV vaccine in South Africa; SECTION VI: INDEPENDENT REVIEW; Case 14: How independent is independent review? Partner notification in a study of sexually-transmitted diseases in Mpumalanga, South Africa; Case 15: Which regulations protect subjects best: preventing HIV status disclosure in a community-based circumcision study in rural Uganda; SECTION VII: INFORMED CONSENT; Case 16: The challenge of informed consent in a genetic epidemiology study of noma in rural Nigeria; Case 17: Compensation to families who consent to research autopsy for their children in a study of malaria mortality in Malawi: respectful or coercive?; SECTION VIII: RESPECT FOR ENROLLED SUBJECTS AND THEIR COMMUNITIES; Case 18: A randomized trial of low-phytate corn for maternal-infant micronutrient deficiency in Guatemala; Case 19: Obligations to participants harmed in the course of the N-9 multi-centre vaginal microbicide trial in South Africa; Case 20: Ethical challenges and controversy in a retrospective study of HIV-1 transmission in Uganda; Case 21: Protecting subjects in a study of domestic violence in South Africa: what services are researchers obligated to provide?; APPENDIX I: ECONOMIC, SOCIAL, HEALTH AND DEVELOPMENT INDICATORS FOR THE CASE COUNTRIES;
Komentarze (0)